Bhaskar Anand - 13 Nov 2021 Form 3 Insider Report for REATA PHARMACEUTICALS INC

Role
VP, Chief Accounting Officer
Signature
/s/ Tracy Herson, attorney-in-fact
Issuer symbol
N/A
Transactions as of
13 Nov 2021
Net transactions value
$0
Form type
3
Filing time
15 Nov 2021, 09:16:38 UTC
Next filing
05 Jan 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding RETA Class A common stock 4,000 13 Nov 2021 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding RETA Stock Option (right to buy) 13 Nov 2021 Class A common stock 15,000 $137.47 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option becomes exercisable 25% on July 12, 2022 and in 12 equal quarterly installments thereafter, subject to continued service through each vesting date.

Remarks:

Exhibit List: Exhibit 24 - Power of Attorney